Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC
Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have...
Gespeichert in:
| Veröffentlicht in: | European journal of surgical oncology 2021-03, Vol.47 (3), p.628-634 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 634 |
|---|---|
| container_issue | 3 |
| container_start_page | 628 |
| container_title | European journal of surgical oncology |
| container_volume | 47 |
| creator | Franken, L.C. Vuijk, F.A. Soer, E.C. Roos, E. Erdmann, J.I. Hooijer, G.K.J. Vahrmeijer, A.L. Gambhir, S.S. van Gulik, T.M. Sarasqueta, A. Farina Verheij, J. Swijnenburg, R.J. |
| description | Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have been developed, selectively binding integrin ανβ6, a cell receptor upregulated in pancreatobiliary malignancies, for both (preoperative) PET and (intraoperative) fluorescent imaging. Here, expression of integrin ανβ6 is evaluated in PHC, intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC) and benign disease mimicking PHC using immunohistochemistry.
Three tissue microarrays (TMA) including 103 PHC tumor cores and sixty tissue samples were selected from resection specimens of pathologically proven PHC (n = 20), ICC (n = 10), HCC (n = 10), metastatic PHC lymph nodes (n = 10) and benign disease (presumed PHC with benign disease at pathological assessment, n = 10). These samples were stained for integrin ανβ6 and quantified using the H-score.
Immunohistochemical staining for integrin ανβ6 showed membranous expression in all twenty PHC whole mount slides (100%) and 93 out of 103 (92%) PHC tumor cores. Mean H-score of PHC samples was 195 ± 71, compared to a mean H-score of 126 ± 57 in benign samples (p = 0.013). In both benign and PHC samples, inflammatory infiltrates and pre-existent peribiliary glands showed integrin ανβ6 expression. The mean H-score across ten ICC was 33 ± 53, which was significantly lower compared to PHC (p |
| doi_str_mv | 10.1016/j.ejso.2020.09.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452100686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0748798320307988</els_id><sourcerecordid>2452100686</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3156-5b24418e2091c074f436b785dce8cea9165617d315987a9a90edde3a2656a4903</originalsourceid><addsrcrecordid>eNp9kMFuEzEQhi0EomnhBTggH8tht2N717uWuKCoUKRK5QBny_HOphOydrA3CB4L7rxCnqmOUjhyGmn0_b9mPsZeCagFCH21qXGTYy1BQg2mBqmfsIVolaykaLunbAFd01ed6dUZO895AwBGdeY5O1MKtGmhXbB0_WOXMGeKgceRU5hxnSjww6_Dn8NvzQcaR0wYZnIzZr7DRPe0dYn7-7h1YU3Ru-QpxMnxy083yzd8THHiKwy0DiWd0WXkE03kv1JY84K8YM9Gt8348nFesC_vrz8vb6rbuw8fl-9uK69Eq6t2JZtG9CjBCF8-GRulV13fDh57j84I3WrRDYU1feeMM4DDgMrJsneNAXXBLk-9uxS_7THPdqLscVvOxrjPVjatFAC61wWVJ9SnmHPC0e4STS79tALs0bXd2KNre3RtwdjiuoReP_bvVxMO_yJ_5Rbg7QnA8uV3wmSzJwweB0roZztE-l__AzmWklY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452100686</pqid></control><display><type>article</type><title>Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Franken, L.C. ; Vuijk, F.A. ; Soer, E.C. ; Roos, E. ; Erdmann, J.I. ; Hooijer, G.K.J. ; Vahrmeijer, A.L. ; Gambhir, S.S. ; van Gulik, T.M. ; Sarasqueta, A. Farina ; Verheij, J. ; Swijnenburg, R.J.</creator><creatorcontrib>Franken, L.C. ; Vuijk, F.A. ; Soer, E.C. ; Roos, E. ; Erdmann, J.I. ; Hooijer, G.K.J. ; Vahrmeijer, A.L. ; Gambhir, S.S. ; van Gulik, T.M. ; Sarasqueta, A. Farina ; Verheij, J. ; Swijnenburg, R.J.</creatorcontrib><description>Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have been developed, selectively binding integrin ανβ6, a cell receptor upregulated in pancreatobiliary malignancies, for both (preoperative) PET and (intraoperative) fluorescent imaging. Here, expression of integrin ανβ6 is evaluated in PHC, intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC) and benign disease mimicking PHC using immunohistochemistry.
Three tissue microarrays (TMA) including 103 PHC tumor cores and sixty tissue samples were selected from resection specimens of pathologically proven PHC (n = 20), ICC (n = 10), HCC (n = 10), metastatic PHC lymph nodes (n = 10) and benign disease (presumed PHC with benign disease at pathological assessment, n = 10). These samples were stained for integrin ανβ6 and quantified using the H-score.
Immunohistochemical staining for integrin ανβ6 showed membranous expression in all twenty PHC whole mount slides (100%) and 93 out of 103 (92%) PHC tumor cores. Mean H-score of PHC samples was 195 ± 71, compared to a mean H-score of 126 ± 57 in benign samples (p = 0.013). In both benign and PHC samples, inflammatory infiltrates and pre-existent peribiliary glands showed integrin ανβ6 expression. The mean H-score across ten ICC was 33 ± 53, which was significantly lower compared to PHC (p < 0.001) but too weak to consistently discriminate ICC from HCC (H-score 0)(p = 0.062).
Integrin ανβ6 is abundantly expressed in PHC and associated metastatic lymph nodes. Expression is significantly higher in PHC as compared to benign disease mimicking PHC, ICC and HCC, emphasizing its potential as a target for tumor-specific molecular imaging.</description><identifier>ISSN: 0748-7983</identifier><identifier>EISSN: 1532-2157</identifier><identifier>DOI: 10.1016/j.ejso.2020.09.026</identifier><identifier>PMID: 33069505</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cholangiocarcinoma ; Diagnostic tool ; Immunohistochemistry ; Integrin ; Molecular imaging</subject><ispartof>European journal of surgical oncology, 2021-03, Vol.47 (3), p.628-634</ispartof><rights>2020 The Authors</rights><rights>Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3156-5b24418e2091c074f436b785dce8cea9165617d315987a9a90edde3a2656a4903</citedby><cites>FETCH-LOGICAL-c3156-5b24418e2091c074f436b785dce8cea9165617d315987a9a90edde3a2656a4903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejso.2020.09.026$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33069505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Franken, L.C.</creatorcontrib><creatorcontrib>Vuijk, F.A.</creatorcontrib><creatorcontrib>Soer, E.C.</creatorcontrib><creatorcontrib>Roos, E.</creatorcontrib><creatorcontrib>Erdmann, J.I.</creatorcontrib><creatorcontrib>Hooijer, G.K.J.</creatorcontrib><creatorcontrib>Vahrmeijer, A.L.</creatorcontrib><creatorcontrib>Gambhir, S.S.</creatorcontrib><creatorcontrib>van Gulik, T.M.</creatorcontrib><creatorcontrib>Sarasqueta, A. Farina</creatorcontrib><creatorcontrib>Verheij, J.</creatorcontrib><creatorcontrib>Swijnenburg, R.J.</creatorcontrib><title>Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC</title><title>European journal of surgical oncology</title><addtitle>Eur J Surg Oncol</addtitle><description>Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have been developed, selectively binding integrin ανβ6, a cell receptor upregulated in pancreatobiliary malignancies, for both (preoperative) PET and (intraoperative) fluorescent imaging. Here, expression of integrin ανβ6 is evaluated in PHC, intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC) and benign disease mimicking PHC using immunohistochemistry.
Three tissue microarrays (TMA) including 103 PHC tumor cores and sixty tissue samples were selected from resection specimens of pathologically proven PHC (n = 20), ICC (n = 10), HCC (n = 10), metastatic PHC lymph nodes (n = 10) and benign disease (presumed PHC with benign disease at pathological assessment, n = 10). These samples were stained for integrin ανβ6 and quantified using the H-score.
Immunohistochemical staining for integrin ανβ6 showed membranous expression in all twenty PHC whole mount slides (100%) and 93 out of 103 (92%) PHC tumor cores. Mean H-score of PHC samples was 195 ± 71, compared to a mean H-score of 126 ± 57 in benign samples (p = 0.013). In both benign and PHC samples, inflammatory infiltrates and pre-existent peribiliary glands showed integrin ανβ6 expression. The mean H-score across ten ICC was 33 ± 53, which was significantly lower compared to PHC (p < 0.001) but too weak to consistently discriminate ICC from HCC (H-score 0)(p = 0.062).
Integrin ανβ6 is abundantly expressed in PHC and associated metastatic lymph nodes. Expression is significantly higher in PHC as compared to benign disease mimicking PHC, ICC and HCC, emphasizing its potential as a target for tumor-specific molecular imaging.</description><subject>Cholangiocarcinoma</subject><subject>Diagnostic tool</subject><subject>Immunohistochemistry</subject><subject>Integrin</subject><subject>Molecular imaging</subject><issn>0748-7983</issn><issn>1532-2157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMFuEzEQhi0EomnhBTggH8tht2N717uWuKCoUKRK5QBny_HOphOydrA3CB4L7rxCnqmOUjhyGmn0_b9mPsZeCagFCH21qXGTYy1BQg2mBqmfsIVolaykaLunbAFd01ed6dUZO895AwBGdeY5O1MKtGmhXbB0_WOXMGeKgceRU5hxnSjww6_Dn8NvzQcaR0wYZnIzZr7DRPe0dYn7-7h1YU3Ru-QpxMnxy083yzd8THHiKwy0DiWd0WXkE03kv1JY84K8YM9Gt8348nFesC_vrz8vb6rbuw8fl-9uK69Eq6t2JZtG9CjBCF8-GRulV13fDh57j84I3WrRDYU1feeMM4DDgMrJsneNAXXBLk-9uxS_7THPdqLscVvOxrjPVjatFAC61wWVJ9SnmHPC0e4STS79tALs0bXd2KNre3RtwdjiuoReP_bvVxMO_yJ_5Rbg7QnA8uV3wmSzJwweB0roZztE-l__AzmWklY</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Franken, L.C.</creator><creator>Vuijk, F.A.</creator><creator>Soer, E.C.</creator><creator>Roos, E.</creator><creator>Erdmann, J.I.</creator><creator>Hooijer, G.K.J.</creator><creator>Vahrmeijer, A.L.</creator><creator>Gambhir, S.S.</creator><creator>van Gulik, T.M.</creator><creator>Sarasqueta, A. Farina</creator><creator>Verheij, J.</creator><creator>Swijnenburg, R.J.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202103</creationdate><title>Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC</title><author>Franken, L.C. ; Vuijk, F.A. ; Soer, E.C. ; Roos, E. ; Erdmann, J.I. ; Hooijer, G.K.J. ; Vahrmeijer, A.L. ; Gambhir, S.S. ; van Gulik, T.M. ; Sarasqueta, A. Farina ; Verheij, J. ; Swijnenburg, R.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3156-5b24418e2091c074f436b785dce8cea9165617d315987a9a90edde3a2656a4903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cholangiocarcinoma</topic><topic>Diagnostic tool</topic><topic>Immunohistochemistry</topic><topic>Integrin</topic><topic>Molecular imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Franken, L.C.</creatorcontrib><creatorcontrib>Vuijk, F.A.</creatorcontrib><creatorcontrib>Soer, E.C.</creatorcontrib><creatorcontrib>Roos, E.</creatorcontrib><creatorcontrib>Erdmann, J.I.</creatorcontrib><creatorcontrib>Hooijer, G.K.J.</creatorcontrib><creatorcontrib>Vahrmeijer, A.L.</creatorcontrib><creatorcontrib>Gambhir, S.S.</creatorcontrib><creatorcontrib>van Gulik, T.M.</creatorcontrib><creatorcontrib>Sarasqueta, A. Farina</creatorcontrib><creatorcontrib>Verheij, J.</creatorcontrib><creatorcontrib>Swijnenburg, R.J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Franken, L.C.</au><au>Vuijk, F.A.</au><au>Soer, E.C.</au><au>Roos, E.</au><au>Erdmann, J.I.</au><au>Hooijer, G.K.J.</au><au>Vahrmeijer, A.L.</au><au>Gambhir, S.S.</au><au>van Gulik, T.M.</au><au>Sarasqueta, A. Farina</au><au>Verheij, J.</au><au>Swijnenburg, R.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC</atitle><jtitle>European journal of surgical oncology</jtitle><addtitle>Eur J Surg Oncol</addtitle><date>2021-03</date><risdate>2021</risdate><volume>47</volume><issue>3</issue><spage>628</spage><epage>634</epage><pages>628-634</pages><issn>0748-7983</issn><eissn>1532-2157</eissn><abstract>Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have been developed, selectively binding integrin ανβ6, a cell receptor upregulated in pancreatobiliary malignancies, for both (preoperative) PET and (intraoperative) fluorescent imaging. Here, expression of integrin ανβ6 is evaluated in PHC, intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC) and benign disease mimicking PHC using immunohistochemistry.
Three tissue microarrays (TMA) including 103 PHC tumor cores and sixty tissue samples were selected from resection specimens of pathologically proven PHC (n = 20), ICC (n = 10), HCC (n = 10), metastatic PHC lymph nodes (n = 10) and benign disease (presumed PHC with benign disease at pathological assessment, n = 10). These samples were stained for integrin ανβ6 and quantified using the H-score.
Immunohistochemical staining for integrin ανβ6 showed membranous expression in all twenty PHC whole mount slides (100%) and 93 out of 103 (92%) PHC tumor cores. Mean H-score of PHC samples was 195 ± 71, compared to a mean H-score of 126 ± 57 in benign samples (p = 0.013). In both benign and PHC samples, inflammatory infiltrates and pre-existent peribiliary glands showed integrin ανβ6 expression. The mean H-score across ten ICC was 33 ± 53, which was significantly lower compared to PHC (p < 0.001) but too weak to consistently discriminate ICC from HCC (H-score 0)(p = 0.062).
Integrin ανβ6 is abundantly expressed in PHC and associated metastatic lymph nodes. Expression is significantly higher in PHC as compared to benign disease mimicking PHC, ICC and HCC, emphasizing its potential as a target for tumor-specific molecular imaging.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33069505</pmid><doi>10.1016/j.ejso.2020.09.026</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0748-7983 |
| ispartof | European journal of surgical oncology, 2021-03, Vol.47 (3), p.628-634 |
| issn | 0748-7983 1532-2157 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2452100686 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Cholangiocarcinoma Diagnostic tool Immunohistochemistry Integrin Molecular imaging |
| title | Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A05%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20integrin%20%CE%B1%CE%BD%CE%B26%20differentiates%20perihilar%20cholangiocarcinoma%20(PHC)%20from%20benign%20disease%20mimicking%20PHC&rft.jtitle=European%20journal%20of%20surgical%20oncology&rft.au=Franken,%20L.C.&rft.date=2021-03&rft.volume=47&rft.issue=3&rft.spage=628&rft.epage=634&rft.pages=628-634&rft.issn=0748-7983&rft.eissn=1532-2157&rft_id=info:doi/10.1016/j.ejso.2020.09.026&rft_dat=%3Cproquest_cross%3E2452100686%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452100686&rft_id=info:pmid/33069505&rft_els_id=S0748798320307988&rfr_iscdi=true |